Suvorexant + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders, Alzheimer Disease
Trial Timeline
May 23, 2016 → Sep 30, 2018
NCT ID
NCT02750306About Suvorexant + Placebo
Suvorexant + Placebo is a phase 3 stage product being developed by Merck for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT02750306. Target conditions include Sleep Initiation and Maintenance Disorders, Alzheimer Disease.
What happened to similar drugs?
20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06655883 | Phase 3 | Recruiting |
| NCT05823844 | Approved | Recruiting |
| NCT04571944 | Phase 3 | Completed |
| NCT03110315 | Approved | Completed |
| NCT02750306 | Phase 3 | Completed |
| NCT02729714 | Approved | Completed |
| NCT02491788 | Approved | Completed |
| NCT02527564 | Approved | Completed |
| NCT01293006 | Phase 1 | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders